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Abstract 
We have used the interaction between module 7 of complement factor H (CFH~7) and a fully sulfated 
heparin tetrasaccharide to exemplify a new approach for studying contributions of basic side-chains to 
the formation of glycosaminoglycan (GAG) : protein complexes. We first employed HISQC and 
H2CN NMR experiments to monitor the side-chain resonances of lysines and arginines in 
15
N, 
13
C-
labelled protein during titrations with a fully sulfated heparin tetrasaccharide under physiological 
conditions. Under identical conditions, and using 
15
N-labelled protein, we then cross-linked 
tetrasaccharide to CFH~7 and confirmed a 1:1 stoichiometry by FT-ICR-MS. We subsequently 
characterized this covalent protein-GAG conjugate by NMR and further MS techniques. MALDI-
TOF MS identified protein fragments obtained via trypsin digestion or chemical fragmentation, 
yielding information concerning the site of GAG attachment. Combining MS and NMR data allowed 
us to identify the side-chain of K405 as the point of attachment of the cross-linked heparin 
oligosaccharide to CFH~7. Based on the analysis of NMR and MS data of the non-covalent and cross-
linked CFH~7 : tetrasaccharide complexes we conclude that the K446 side-chain is not essential for 
binding of the tetrasaccharide, despite the large chemical shift perturbations of its backbone amide 
15
N 
and 
1
H resonances during titrations. We show that R444 provides the most important charge-charge 
interaction within a C-terminal heparin-binding sub-site of CFH~7, while side-chains of R404, K405 
and K388 are the predominant contributors to an N-terminal binding sub-site located in the immediate 
vicinity of residue 402, which is implicated in age-related macular degeneration (AMD). 
 
Introduction 
Glycosaminoglycans (GAGs) are linear polysaccharides found ubiquitously on animal cell surfaces 
and in the extracellular matrix. GAGs usually occur linked to protein cores as proteoglycans, and in 
most cases accomplish their biological functions through interactions with ligand proteins
1-4
. Such 
interactions have a strong electrostatic component mediated by the negatively charged functional 
groups of GAGs (sulfates, sulfonamides, and carboxyl groups) and positively charged amino-acid 
side-chains of proteins (lysines, arginines and occasionally histidines). In enzymes which are involved 
in GAG biosynthesis and degradation, GAGs bind in deep canyons and clefts
5
. In complexes with 
growth factors, however, GAGs often sit in shallow grooves on protein surfaces
6-8
, making these 
interactions less specific than protein-protein interactions. Charge density, rather than a requirement 
for a specific structural motif, is often sufficient for complex formation
9-11
. A well documented 
exception is the interaction of a heparin pentasaccharide with antithrombin III which requires a very 
specific GAG motif
12,13
.  
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Nonetheless, GAG composition varies depending on the type and developmental stage of the tissue in 
which they are expressed
14-16
, hinting at the functional relevance of subtle structural variations. 
Indeed, changes in GAG structure and composition have been identified as possible biomarkers for 
cancer
17,18
. Developing new methods for the characterization of protein-GAG complexes
19
 is therefore 
important for our understanding of the biological roles of GAGs and essential for realizing their 
therapeutic potential
10
. 
The growing awareness of the role played by heparan sulfate (HS) in cell-cell communication and the 
potential applications of cross-linked heparin-protein conjugates for medical purposes underline the 
importance of structural elucidation of such constructs. HS/heparin chains cross-linked to protein are 
likely to be more stable to enzymatic degradation than the free GAGs. Covalent protein-GAG 
conjugates may also be more potent in the formation of ternary complexes, such as with signaling 
receptors, than transient, non-covalent protein-GAG complexes
20
. Recently, a synthetic CD4–HS 
glycoconjugate was shown to inhibit CCR5- and CXCR4-mediated HIV-1 attachment and viral 
entry
21
. 
In this study we present novel approaches for the characterization of non-covalent protein-GAG 
complexes and covalently cross-linked protein-GAG conjugates, in solution, by a combination of 
NMR spectroscopy and mass spectrometry. Our methodology is illustrated using the interaction 
between HS and module 7 of human complement factor H (CFH~7). Mature HS contains variably 
sulfated domains interrupted by domains essentially lacking sulfation
22
 and, typically, proteins bind to 
the highly sulfated domains
23
. Consequently, heparin, which shares an identical carbohydrate skeleton 
with HS but displays a higher and more evenly distributed level of sulfation, is often used in structural 
studies as a HS mimetic, as is the case in the present study. 
CFH, the main fluid-phase regulator of the alternative pathway of complement
24
, is a 155-kDa 
heparin-binding protein consisting of twenty ~7-kDa complement control protein modules (CCPs). 
CCPs have a prolate ellipsoid shape, high β-sheet content and two conserved disulfide bonds per 
module. They are connected by linkers of 3-8 residues, giving CFH the appearance of 20 beads on a 
string. By binding to HS or other cell surface polyanions
25
, CFH protects host cells from complement 
attack
26,27
. This interaction is thought to lie at the centre of host-cell protection from the innate 
immune system, and is particularly important for cells lacking alternative membrane-bound 
regulators. 
The Y402H single nucleotide polymorphism in CFH~7, present in about 30% of the population, is 
associated (in homozygous individuals) with a 7-fold increase in the occurrence of age-related 
macular degeneration (AMD)
28-31
. As CFH~7 contributes directly to one of the two principal heparin-
binding sites in CFH, it was proposed that a change in polyanion-binding properties of the histidine 
allotype compromises the ability of CFH to protect the Bruch’s membrane from complement-
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mediated damage. This membrane underlies the retinal pigment epithelium, and its damage triggers 
inflammatory processes eventually leading to AMD onset
32
. In this study we have used the Y402 
variant, which is referred to from now on as CFH~7. Solution structures of both variants of CFH~7 
have been previously solved by NMR
33
. The crystal structure of the disease-linked variant H402, in 
the context of the triple module CFH~6-8 complexed with sucrose octasulfate (SOS), has also been 
determined previously
34
. 
Protein-GAG interactions are typically weak and fall into the fast-exchange regime on the NMR 
timescale. This facilitates tracking of ligand-induced chemical shift perturbations in 
1
H, 
15
N-HSQC 
spectra of 
15
N-labelled proteins through chemical-shift averaging of free and bound protein. However, 
such analysis is generally limited to backbone NH resonances. A lack of chemical shift perturbations 
of the backbone NH atoms belonging to basic residues is a poor indicator of non-involvement of their 
side-chains in GAG binding while, vice versa, changes in backbone NH chemical shifts do not 
necessarily imply the involvement of the corresponding arginine and lysine side-chains. In order to 
complement backbone NH chemical shift perturbation data, we monitored lysine N
ζ
H
ζ
3
+
 and arginine 
N
ε
H
ε
 resonances during GAG titrations. In addition, we used chemical cross-linking as a means to 
probe the roles of individual lysine side-chains in the formation of protein-GAG complexes. We 
employed a zero-length cross-linking technique, originally designed to cross-link proteins through 
contacts between primary amino and carboxylate groups
35
. This methodology
 
couples the amino group 
of a lysine side-chain to the activated carboxylate of a GAG oligosaccharide
36-39
. Assuming that the 
binding mode of the activated carbohydrate is similar to that of the unmodified oligosaccharide, 
formation of an amide bond provides evidence for spatial proximity between a specific lysine side-
chain and a carboxyl group of the oligosaccharide. 
 
Experimental Section 
Preparation of fully sulfated heparin tetrasaccharide 
Fully sulfated tetrasaccharide, UA(2S)-GlcNS(6S)-IdoA(2S)-GlcNS(6S), was produced by 
controlled, partial, heparinase I digestion of low-molecular weight heparin, and subsequent 
purification by gel-filtration and ion-exchange chromatography as described previously
33
. The purity 
was checked by 
1
H-NMR and concentrations were determined using absorbance at 232 nm with a 
molar absorption coefficient of 5200 M
-1
 cm
-1 40
. 
 
Preparation of CFH~7 
A protein construct containing CFH residues 386 to 446 (Y402) was cloned into the Pichia pastoris 
expression vector pPICZαB (Invitrogen) and transformed into the P. pastoris strain KM71H 
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(Invitrogen). 
15
N-labelled protein was expressed in baffled shaker flasks, or a Bioflow 3000 fermenter, 
using 
15
NH4 as the sole nitrogen source. CFH~7 was purified from the supernatant using cation-
exchange chromatography at pH 6.0
33
. Purity was checked by SDS-PAGE and MALDI-TOF MS. The 
protein consisted of a major fraction with the N-terminal truncated artifact EAAG and a minor 
fraction with the full artifact EAEAAG. The former component could readily be purified on a Mono-S 
cation-exchange column (GE Healthcare) using 20 mM potassium phosphate, pH 6.0, and a linear 
gradient to 1 M NaCl. 
13
C, 
15
N-labelled CFH~7, as prepared previously
33
, was also used in this study. 
Protein concentrations were determined using absorbance at 280 nm (calculated extinction coefficient 
= 13200 M
-1
cm
-1
). 
 
Zero-length cross-linking of a protein-GAG complex
35
 
Desalted fully sulfated heparin tetrasaccharide (0.2 mg), 22 mM 1-ethyl-3-[3-dimethylaminopropyl]-
carbodiimide hydrochloride (EDC) and 30 mM sulfo-N-hydroxysuccinimide (sulfo-NHS) in a total 
volume of 1 mL of 50 mM 2-(N-morpholino)ethanesulfonic acid (MES), pH 6.0 were incubated at 25 
°C for 15 min. The activated tetrasaccharide was recovered from the cross-linking reagents by quick 
passage over a PD-10 desalting column (GE Healthcare) and immediately mixed with 2.3 mg of 
CFH~7 in 1 ml of 50 mM Tris-HCl, pH 6.0. The cross-linking reaction mixture was incubated at 25 
°C for 3 hrs before purification by cation-exchange chromatography on a Mono-S column (GE 
Healthcare) with 20 mM potassium phosphate, pH 6.0 as the running buffer. The free protein bound to 
the column, while the anionic, cross-linked protein-GAG was collected in the flow-through. Mono-
cross-linking was confirmed by MS after buffer exchange into 50 mM ammonium acetate pH 4.5 
using TubeODialyzers (G Biosciences) with Mr cut-off = 1 kDa. 
 
NMR experiments 
All NMR experiments, with the exception of 
15
N-relaxation measurements, were conducted on a 600 
MHz Bruker AVANCE spectrometer equipped with a 5-mm cryogenic probe. Heteronuclear in-phase 
single quantum coherence (HISQC)
41
 spectra of free and cross-linked protein were collected in 20 
mM potassium phosphate, pH 3.0) at 283 K on a uniformly 
15
N-labelled sample of 50 µM CFH~7. 
HISQC spectra were acquired using a coaxial NMR tube with the capillary (Norell) filled with D2O to 
avoid proton-deuterium exchange. The 
15
N offset was set to 33 ppm and a spectral width of 5 ppm 
was used in the indirectly detected dimension. A 900 μs 180o 15N rSNOB pulse42 was applied during 
the final refocusing period. Typically, 64 increments were acquired in the 
15
N dimension resulting in 
the acquisition time of 106 ms in t1. Spectra were typically acquired in < 1 h. Assignment of the lysine 
N
ζ
H
ζ
3
+
 cross peaks was accomplished by collecting a (H)CCENH3
41
 spectrum on a 0.5 mM sample of 
free, uniformly 
13
C- and 
15
N-labelled CFH~7 in 20 mM potassium phosphate, pH 3.0 at 283 K, and 
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comparison of the C
α
-C
ε
 chemical shifts with a previously assigned (H)C(CO)NH-TOCSY 
spectrum
33,43
 collected at pH 5.2 (20 mM sodium acetate) and 298 K (Fig. 1S). A titration of 0.1 mM 
13
C, 
15
N-CFH~7 with the heparin tetrasaccharide was conducted in 20 mM potassium phosphate, pH 
7.4 at 298 K using protein:GAG molar ratios of 1:0, 1:0.5, 1:1 and 1:2 and monitored by the 2D H2CN 
experiments
44
. 
15
N and 
13
C offsets of 33 and 42 ppm were used. All 
15
N pulses were nonselective. A 
1500 μs 180o 13N reBURP pulse45 was applied during the final refocusing period. Typically, 64 or 32 
increments were acquired in the 
15
N or 
13
C dimensions resulting in the acquisition times of 106 and 21 
ms. 2D 
15
N and 
13
C planes were acquired in 2.5 and 1 h, respectively. Lysine cross peaks were 
assigned using the N
ζ
-chemical shifts, as obtained for the HISQC spectra, and transferred with the 
help of further 2D H2CN spectra collected at intermediate temperatures and pH values. 
1
H-
15
N HSQC 
spectra were acquired using standard parameters and 
15
N offset of 120 ppm. Evaluation and 
assignment of protein NMR spectra were done using CcpNmr Analysis
46
. 
15
N-relaxation data were 
acquired on an 800-MHz NMR instrument equipped with a 5-mm cryogenic probe using 25 μM 
CFH~7 and 40 μM tetrasaccharide in 20 mM sodium acetate, pH 5.0 at 298 K. The intensities of 
individual cross peaks, obtained by deconvolution of NH signals in the Bruker TOPSPIN program, 
were fitted to an exponential decay in Gnuplot. 
 
Trypsin digestion 
Samples of 65 μg CFH~7, either free or as cross-linked conjugate, were treated with 0.25 mM 
dithiothreiol (DTT) and 8 M urea in a total volume of 400 μL and incubated at 75 °C for 1 hr. The 
unfolded and reduced samples were alkylated by incubation with 125 mM iodoacetamide at room 
temperature (total volume 500 μL). Dialysis into 50 mM ammonium acetate, pH 7.4, was conducted 
overnight before 2.5 µg trypsin (sequencing grade, Promega) was added in a volume of 500 μL. 
Digestion proceeded at 37 °C for 1.5 hrs and trypsin was then reversibly deactivated by reducing the 
pH to 4.0 with 1 M acetic acid and cooling the samples to 4 °C. MALDI-TOF MS was used to assess 
the degree of digestion. For complete digestion, trypsin was re-activated by raising the sample pH to 
8.2 and incubating overnight at 37 °C. 
 
Microwave-assisted acid hydrolysis 
Cross-linked conjugate (30 μL of 80 μM) was mixed with 0.1 mM DTT and 20% trifluoroacetic acid 
(TFA) in a total volume of 50 μL in a 1.5-mL Eppendorf microcentrifuge tube47. The sample was 
placed within a glass beaker in a domestic microwave oven, along with a second glass beaker 
containing roughly 100 mL water for absorption of excess radiation, and heated with 950 Watts for 6 
mins in two-minute steps. After each step, the sample was opened to release the pressure. The sample 
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was then subjected to MALDI-TOF MS. The web server ProSight PTM 
(https://prosightptm.scs.uiuc.edu/) was used to assist in peptide identification. 
 
Mass spectrometry 
MALDI-TOF spectra were acquired on a Voyager-DE STR MALDI-TOF instrument (Applied 
Biosystems) with a nitrogen laser in positive mode. Matrices used were sinapinic acid for protein 
samples and alpha-cyano-4-hydroxy-cinnamic acid (CHCA) for peptides. Matrices were prepared by 
mixing 15 mg sinapinic acid or 10 mg CHCA with 400 μL double-distilled water, 100 μL 3% TFA 
and 500 μL acetonitrile, followed by sonication for 3 mins. Generally, 0.5 μL of protein or peptide 
samples were mixed with 0.5 μL of the appropriate matrix directly on the MALDI-TOF plate. The 
laser intensity was adjusted manually for each sample. Accurate mass spectra were recorded using a 
12 T Apex-Qe FT-ICR mass spectrometer (Bruker Daltonics, Billerica, MA). Sample infusion was 
performed in positive-ion mode, using a TriVersa NanoMate (Advion Biosciences, Ithica, NY) chip-
based nanoelectrospray ionisation (nanoESI) robot. The broadband spectrum was acquired from 100 
accumulations using a time domain data size of 512k word, prior to Fourier transformation. The mass 
error between the most abundant isotope peak measured at 1693.09 m/z and the peak in the simulated 
pattern was 8 ppm. The mass of the cross-linked CFH~7 : tetrasaccharide conjugate was calculated as 
the individual masses of the free protein plus tetrasaccharide minus the one water molecule eliminated 
during cross-linking; all sulfates and the remaining carboxyl group in the GAG moiety were 
considered to be protonated. 
 
Results 
Titration of CFH~7 with fully sulfated heparin tetrasaccharide monitored by 
1
H, 
15
N-HSQC 
Combined chemical shift changes of backbone NH resonances at the end point of the CFH~7 titration 
with tetrasaccharide are illustrated in Fig. 1a. Residues with resonances most affected by binding are 
highlighted on the lowest energy solution structure
33
 of CFH~7 in Fig. 1b. Several of these are in 
close proximity to Y402, the residue whose variation is linked to AMD. CFH~7 contains five lysines 
and four arginines which are also highlighted. Five of these basic residues are located towards the N-
terminus, two occur within the middle of the module, while the two remaining ones are located close 
to the C-terminus. Only three (R404, K405 and K446) out of these nine residues had backbone NH 
15
N and 
1
H resonances significantly affected by binding of the tetrasaccharide (Fig 1). 
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Figure 1. (a) Combined 
1
H and 
15
N chemical shift changes of CFH~7 during 
1
H, 
15
N-HSQC titrations 
(molar ration of protein : carbohydrate = 1 : 8) with fully sulfated heparin tetrasaccharide. Residues 
with chemical shift differences of 0.4-0.6 ppm or > 0.6 ppm are highlighted in yellow or green, 
respectively. Not observable proline residues are shown in gray and given the arbitrary combined 
chemical shift difference of 0.005 ppm. (b) NMR structure of CFH~7 (pdb entry 2JGX) displaying in 
yellow or green residues highlighted in (a). The AMD-associated residue 402 is shown in cyan. Side-
chains of the remaining basic residues are shown in red. Figure rendered using Sybyl (Tripos). 
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Dimerisation of CFH~7 caused by heparin tetrasaccharide 
As a consequence of the helical nature of heparin
48-50
, its negative charges are distributed on both 
faces of the helix and can be presented to proteins on either side. Indeed a 1:2 GAG:protein complex 
has been observed for GAG fragments as short as tetrasaccharides, e.g. in the crystal structure of 
acidic fibroblast growth factor in complex with a fully sulfated heparin tetrasaccharide
6
. In solution, 
dimerisation would be expected to slow down molecular tumbling and affect 
15
N NMR relaxation 
times. In the very fast monomer-dimer exchange approximation, no additional broadening of signals 
results from chemical exchange, thus the measured relaxation times should reflect the weighted 
average of the relaxation times of monomeric and dimeric species
51
. The majority of backbone NH 
signals of CFH~7 exhibited marginal chemical shift changes upon addition of tetrasaccharide, 
validating this approximation. The 
15
N T1 and T2 relaxation times were measured
52
 in a series of 1D 
experiments acquired at 800 MHz, and the rotational correlation time, τc, of CFH~7 was determined 
using the R2R1 program (A. G. Palmer III, Columbia University). For free CFH~7 and its complex 
with tetrasaccharide these were measured as 4.7 and 8.4 ns, respectively. Analogous data for the 402H 
isoform yielded τc values of 5.0 and 8.5 ns, respectively. These data imply that binding to the heparin 
tetrasaccharide promotes dimerisation of both CFH~7 variants. 
 
Monitoring of lysine and arginine side-chain resonances during titrations 
The lysine N
ζ
H
ζ
3
+
 signals are very rarely observed in standard 
1
H, 
15
N-HSQC spectra. This is because 
side-chain protons exchange rapidly with water under near physiological conditions, and also N
ζ
 
nuclei resonate approximately 90 ppm away from backbone nitrogen resonances and are inverted 
inefficiently by typical 80 s 15N pulses. Similarly, although to a lesser extent, NεHε resonances of 
arginines are difficult to observe at neutral pH. It was demonstrated recently that refocusing of lysine 
2H3
+ζ
zN
ζ
x,y coherences prior to the t1 period allows monitoring of N
ζ
x,y coherences in a HISQC 
experiment
41
; in-phase N
ζ
x,y coherences have longer relaxation times and are not quenched by 
exchange with water. Nevertheless, the HISQC experiment generally works well only if the exchange 
of H
ζ
 protons with water during the INEPT steps is slowed down by lowering the pH (2-4) and the 
temperature (5-15 
o
C). Under physiological conditions, N
ζ
H
ζ
3
+
 resonances were detected by the 
HISQC experiment only in the presence of stable salt bridges
53,54
 or in protein complexes
41
 where 
lysine side-chains NH atoms are protected from rapid exchange with water. In the case of CFH~7, 
free or in complex with the tetrasaccharide, no lysine side-chain resonances were observed in the 
HISQC experiment under physiological conditions. 
On the other hand, all five N
ζ
H
ζ
3
+
 cross peaks appeared in the HISQC spectrum of free CFH~7 (Fig. 
2) when the temperature was lowered to 283 K and the pH was adjusted to 3.0. A 
1
H, 
15
N-HSQC 
spectrum collected under these conditions confirmed that the protein was folded (data not shown). 
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The N
ζ
H
ζ
3
+
 resonances were subsequently assigned through a comparison of the lysine side-chain 
carbon frequencies in 3D (H)CCENH3
41
 and (H)C(CO)NH-TOCSY
43
 spectra (Fig. 1S). Despite the 
fact that these spectra were acquired at different pH-values, the match between individual CH 
chemical shifts was good, which is consistent with the remarkable stability of CCP modules
55
. 
 
 
Figure 2. Superimposed 
1
H, 
15
N- HISQC spectra of the free (black) and cross-linked protein (green) 
at pH 3.0, 283 K.  
 
Unfortunately, addition of tetrasaccharide to 
15
N-labeled CFH~7 at pH 3.0 and 283 K caused it to 
precipitate. We therefore decided to follow complex formation at pH 7.4 and 298 K via resonances of 
non-exchangeable lysine H
ε
, C
ε
 (or N
ζ
) side-chain atoms using a 
15
N, 
13
C-labelled sample. This was 
accomplished using the 3D H2CN experiment
44
 which uses the non-exchangeable H
ε
 protons for 
excitation and detection and indirectly monitors N
ζ
 and C
ε
 chemical shifts. Sufficient resolution was 
achieved by recording the H
ε
N
ζ
 or H
ε
C
ε
 2D planes, rather than acquiring full 3D spectra. H2CN 
spectra of the complex were assigned by recording the H
ε
N
ζ
 plane of the H2CN experiments on a free 
protein sample and comparing the 
15
N chemical shifts with those obtained from the HISQC 
experiments. Both H2CN planes were acquired during the course of a titration of CFH~7 with 
tetrasaccharide. The H
ε
C
ε
-plane showed a better resolution of lysine resonances than the H
ε
N
ζ
 plane. 
Only two lysine residues (K405 and K388) exhibited significant chemical shift changes after addition 
of tetrasaccharide (Fig 3a). 
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Figure 3. Lysine or arginine side-chain resonances monitored using the H2CN experiment during the 
titration of CFH~7 with heparin tetrasaccharide at pH 7.4 and 298 K. (a) H
ε
C
ε
 plane showing the 
lysine signals with protein : ligand ratios of 1:0 (black), 1:0.5 (red), 1:1 (pink), 1:2 (green). (b) H
δ
N
ε
 
plane showing the arginine signals with protein : ligand ratios of 1:0 (gray), 1:0.5 (red), 1:1 (green), 
1:2 (blue). 
 
The same experiment also monitors the movement of arginine H
δ
, C
δ
 (or N
ε
) side-chain resonances, 
which appear as folded peaks when a small spectral width centered at 33 ppm is used in the indirectly 
detected 
15
N dimension. The chemical shift perturbations of arginine N
ε
H
ε
 resonances were smaller 
than those of H
ε
N
ζ
 of lysines, which can be explained by the fact that it is the quanidino group of 
arginines that is involved in the electrostatic interaction and not N
ε
 
56
. For arginine residues, the H
δ
N
ε
 
plane (Fig. 3b) showed better resolution than the H
δ
C
δ 
plane. Of the four arginine residues, only R404 
has non-equivalent CH2 protons. This residue exhibited the largest cross peak movement during the 
titration. The second largest changes were observed for the H
δ
N
ε
 resonances of R444, while the 
remaining two signals, belonging to R387 and R441, moved only very little. 
 
Zero-length cross-linking of protein-GAG complexes 
The heparin tetrasaccharide was cross-linked to CFH~7 as described in the Experimental section. The 
products were separated by cation-exchange chromatography at pH 6.0 (Fig. 4), and fractions were 
analyzed by positive mode MALDI-TOF MS. Unlike the free protein that binds and is eluted with 
0.3M NaCl (7320.5 Da peak in Fig. 4), the cross-linked CFH~7: heparin tetrasaccharide conjugate, 
being more anionic, did not bind and was recovered in the flow through. It yielded the strongest peak 
at 8378.4 Da – a Mr corresponding to CFH~7 cross-linked to a single tetrasaccharide that has lost one 
sulfate group. A mass difference of 80 Da (equivalent to the mass of SO3) between additional peaks 
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indicated further loss of sulfate groups during MS analysis. Minor compounds eluting at salt 
concentrations < 0.3 M correspond to modifications of the free protein due to the remaining cross-
linking reagent after separation of the activated GAG. The peak with a MW > 15 kDa is likely a 
product of protein-protein cross-linking. 
 
 
Figure 4. Cation-exchange chromatography at pH 6.0 of the reaction mixture after cross-linking 
CFH~7 to fully sulphated heparin tetrasaccharide. Molecular masses of selected peaks were 
determined by MALDI-TOF MS. 
 
Characterization of the cross-linked conjugate by NMR and MS 
A 
1
H, 
15
N-HSQC spectrum of the cross-linked CFH~7-tetrasaccharide conjugate, recorded at 298 K 
and pH 6.0 (Fig. 2S), exhibited almost complete loss of signals from the N-terminal portion, as shown 
on the protein structure in Fig. 5. Some of the remaining cross peaks had distorted line-shapes, while 
others were as sharp as those seen in the spectrum of the free protein. None of the three, N-terminal 
lysine residues showed cross peaks in the HISQC spectrum of the conjugate (Fig. 2) , while the K424 
and K446 N
ζ
H
ζ
3
+
cross peaks were clearly visible and experienced almost no changes in chemical 
shifts or line widths. 
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Figure 5. NMR structure of CFH~7 (pdb entry 2JGX) showing residues whose NH backbone (red) or 
side-chain (yellow) resonances are missing in the 
1
H, 
15
N-HSQC spectrum of the cross-linked sample. 
The orientation of the molecule on the right is identical to that in Fig. 1b. Figure rendered using 
Sybyl. 
 
Accurate FT-ICR-MS measurements confirmed that cross-linking produced a covalent 1:1 conjugate 
of tetrasaccharide and CFH~7 with a Mr of 8460.5 Da. (Fig 6). ECD and in-source fragmentation 
resulted in progressive sulfate loss but not in significant protein fragmentation, confirming the 
stability of the cross-linked conjugate and the lability of NS/OS bonds. The high stability of the 
conjugate in MS-MS experiments is likely caused by the low largest obtainable charge state (+5) and 
is a result of the presence of seven negative charges on the tetrasaccharide. Peptide analysis after 
trypsin digestion or chemical cleavage was therefore employed to investigate the site of the cross-
linking. 
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Figure 6. FTICR-MS spectrum of CFH~7 cross-linked to fully sulfated heparin tetrasaccharide. A 
simulation of the isotope pattern for a charge state of +5 (red triangles) corresponds well to the 
measured main peak (black). 
 
Trypsin digestion and chemical cleavage of the cross-linked species 
As high concentrations (0.1 M) of DTT alone did not reduce the two disulfide bonds within CFH~7, 
the complex was denatured by combined treatment with 8 M urea and 0.25 M DTT, prior to alkylation 
with iodoacetamide. Successful reduction and alkylation was confirmed by MALDI-TOF MS. Protein 
fragments from the subsequent trypsin digest, with MWs of 1470.6 Da, 1879.7 Da and 2129.8 Da 
(Fig. 3S), were identified as peptides S411IDVACHPGYALPK424, A425QTTVTCMENGWSPTPR441 
and K388CYFPYLENGYNQNYGR404 (theoretical masses of 1470.7 Da, 1879.0 Da and 2129.3 Da, 
respectively). These fragments included lysine residues K388 and K424, indicating that these had not 
been modified by cross-linking. Additionally, the generation of the first of these peptides (S411-K424) 
suggests that K410 is also unmodified, as this residue is still recognized, and cleaved at by trypsin. 
Chemical fragmentation using TFA and microwave radiation
47
 undertaken as a complementary 
approach yielded fragments which differed from those obtained using trypsin. The chemical cleavage 
effectively ‘sequenced’ the C-terminus of the protein (Fig. 4S), and established that K446 is also 
unmodified. In summary, the MS techniques directly showed that residues K388, K424 and K446 are 
not modified by cross-linking, and implied that K410 also remains unmodified. Thus, according to 
these experiments, K405 is the point of attachment of tetrasaccharide to CFH~7 within the conjugate.  
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Discussion 
Previous studies based on standard 
1
H, 
15
N-HSQC spectra identified two GAG-binding sites in 
CFH~7 located near the C- and N-termini
33,34
. These sites may now be analyzed separately in the light 
of the experimental results presented above. Four basic residues could potentially contribute to the 
binding at the C-terminus: K424, R441, R444 and K446. Of these only R444 showed a significant 
movement of side-chain resonances in the titration experiments monitored by H2CN spectra (Fig 3b). 
At the same time backbone NH resonances of R444 remained relatively unperturbed. Inverse 
observations were made for K446, where backbone NH resonances were perturbed significantly upon 
titration while the side-chain resonances did not move at all (Fig 3a). The HISQC spectrum of the 
cross linked species showed N
ζ
H
ζ
3
+ 
cross peaks of K424 and K446 that were also unchanged 
compared to the free protein. These observations were supported by MS analysis of the conjugate that 
identified peptide fragments containing unmodified lysines at these positions. We therefore infer that 
the side-chain of R444 is the main contributor to charge-charge interactions at the C-terminal binding 
site, while the K446 backbone amide forms a hydrogen bond to the tetrasaccharide. Involvement of 
the R444 side-chain in the binding is in agreement with this side-chain coordinating a SOS molecule 
in the crystal structure of the CFH~6-8H-SOS complex
34
. Overall, the C-terminal binding site is 
weaker than the N-terminal one. This suggestion is supported by the limited movement of backbone 
and side chain resonances, and also by the lack of cross-linking of tetrasaccharide to this region of the 
protein. 
Amongst the five basic residues of the N-terminal binding site of CFH~7, R387, K388, R404, K405 
and K410, the H2CN experiment identified side-chain resonances of K388, R404 and K405 as 
experiencing the largest chemical shift changes during titration with tetrasaccharide. Of these, K388 
did not show perturbation of the backbone NH cross peaks, while the other two residues did. The 
1
H, 
15
N-HSQC and HISQC spectra of the cross-linked conjugate lacked cross peaks from residues in the 
N-terminal portion of the protein, which could be explained by an intermediate-timescale 
conformational exchange induced by the attachment of the tetrasaccharide (Fig. 2, Fig. 2S). MS 
analysis of the trypsin digest of the conjugate established that K388 and K410 were not modified, 
leaving only one lysine residue, K405, available for the tetrasaccharide attachment. Combined MS 
and NMR data therefore allow us to locate the site of tetrasaccharide cross-linking to the side chain of 
K405. 
Overall, we conclude that the side-chains of K405, R404, and K388 provide most of the charge-
charge interactions of the N-terminal HS/heparin-binding site of CFH~7. This is in agreement with 
mutagenesis studies which showed that the mutations K405A and R404A significantly reduced 
heparin binding to CFH~6-8
57
. The K388A mutation caused a smaller decrease in heparin affinity
57
, 
but in the context of a R387A/K388A double mutation
58
 the effects were substantial. Comparison of 
Page 15 of 21 
our solution data with the X-ray structure of the CFH~6-8(H402)-SOS complex
34
 is not 
straightforward for several reasons. The two studies use different proteins (triple vs single module, 
and H402 vs Y402 variant) and different ligands (SOS vs fully sulfated heparin tetrasaccharide). 
Multiple SOS molecules are seen in the crystal structure of the CFH~6-8 (H402)-SOS complex, 
where several CFH~6-8 molecules contribute to the binding of each SOS molecule in an overall 
stoichiometry of 1:1. It seems possible that the observed arrangement in the protein crystal, prepared 
by co-crystallisation, reflects a tendency of CFH~6-8 to oligomerize in solution in the presence of a 
highly sulfated GAG mimic. This hypothesis is supported by our 
15
N relaxation measurements which 
found increased self-association of both CFH~7 variants in the presence of heparin tetrasaccharide. 
The X-ray structure shows hydrogen bonds between the sulfate and backbone NH of F391 in the 
immediate vicinity of Y402. This is consistent with the movement of NH backbone resonances Y390 
and F391 observed in our titrations of CFH~7 with the tetrasaccharide (Fig 1a). 
Our data position the tetrasaccharide near the three basic residues K405, R404, and K388, and thus 
provide strong experimental evidence for its binding in close proximity to Y402. This is in agreement 
with previous docking studies of a highly sulfated heparin pentasaccharide
57
. It was suggested 
previously that the mode of binding of SOS in the CFH~6-8 (H402)-SOS complex
34
 is incompatible 
with the position of the Y402 side chain found in the solution structure of CFH~7 (Y402)
33
. It is 
therefore likely that different sulfated molecules interact differently with the N-terminal binding site 
of CFH~7. Differences were also observed in binding to Y402 and H402 of heparin species with 
various levels and patterns of sulfation
57
. More atomic resolution data will be needed to explain these 
observations. Given the difficulties in crystallizing factor H modules in the presence of GAGs, NMR 
will play an important role in these investigations, which will benefit from the methodology outlined 
in this work. 
Summarizing our findings from the methodological point of view, we have shown that the H2CN 
experiment
34
,
 
although requiring a double-labeled sample, is a very useful tool for monitoring lysine 
and arginine side-chain resonances of protein-GAG complexes under physiological conditions. The 
usefulness of the HISQC experiment is limited due to the fact that it requires non-physiological 
conditions. It can, however, provided useful information about covalently-linked, protein-GAG 
glycoconjugates. 
Peptide analysis after trypsin digestion and chemical cleavage was employed to locate the cross-
linking site. Four lysine residues out of five were shown, unambiguously, to be unmodified within a 
conjugate consisting of a tetrasaccharide moiety chemically cross-linked to a lysine side chain. It 
must, therefore, be the case that K405 is the site at which the tetrasaccharide is attached. No peptide 
containing the K405 – tetrasaccharide conjugate could be detected by MALDI-TOF, presumably due 
to the large overall negative charge predicted for such a species. If identification of a GAG-peptide 
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construct were needed, negative-ion ES-MS spectrometry would be an option
21
. Another potential 
hurdle to positive identification of the conjugated proteolytic fragment, however, is that covalently 
attached oligosaccharides might compromise access by trypsin or Lys-C not just to the cleavage site 
directly following the conjugated lysine residue but also to nearby cleavage sites. This is likely to be a 
particular problem with GAG-binding proteins since they often contain clusters of lysine and arginine 
residues. 
In a related zero-length cross-linking approach reported previously
38
 a GAG-binding protein was 
cross-linked to heparin immobilised on beads. The glycoconjugate was then subjected to proteolytic 
digestion on the beads, with subsequent identification of the cross-linked peptides by N-terminal 
sequencing, which gives a “gap” at the position of the cross-linked amino acid residue. This solid 
phase assay requires immobilised GAGs, and only inhomogeneous heparin preparations are presently 
commercially available in this form. The authors of this approach also observed some cross-linking to 
arginines. This was not the case in our study as all arginine residues were recognized by trypsin, and 
fragments containing unmodified arginines were also present in the chemically-cleaved material. Our 
approach, being solution-based, can be equally applied to protein cross-linking to any type, size, and 
specific sequence of GAG oligosaccharides. Furthermore, whereas N-terminal protein sequencing is 
becoming increasingly less available, cross-linking in solution is more amenable to MS techniques, 
the application of which is rapidly evolving for GAGs
59,60,61
. 
 
Conclusions 
We have pointed out the shortcomings of the exclusive use of 
1
H, 
15
N-HSQC spectra for chemical 
shift mapping of GAG-binding sites on proteins. We found that use of the HISQC experiment for 
monitoring chemical-shift perturbations of side-chain amine groups is, in the case of a weak complex, 
limited to low pH and low temperature, although it is potentially useful for the analysis of cross-
linked species. We demonstrated that the H2CN experiment provides a more useful route for 
characterization of the contributions of individual lysine and arginine side-chains to ligand binding 
under physiological conditions. Furthermore, we showed that chemical cross-linking, as analyzed by 
proteolytic or chemical fragmentation and MS, provides a valuable complement to the NMR-based 
studies. Combining NMR and MS data, we inferred that two GAG-binding sites exist in CFH~7 
(Y402) in solution, with the R444 side-chain and the K446 backbone amide being the dominant 
contributors to charge-charge interactions in the C-terminal binding site, while the side-chains of 
R404, K405 and K388 are most important for the N-terminal binding site that lies in the immediate 
vicinity of residue 402, which is implicated in AMD. The methods proposed here, using non-covalent 
complexes as well as a cross-linked protein-GAG conjugate, have the potential to aid structural 
investigations in the growing field of protein-GAG interactions.  
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